Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Ritchie

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Pharmacotherapy|April 10, 2002
Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: case report and literature reviewKristin E Mondy, Bruce Haughey, Philip L Custer, et al.
Clinical Therapeutics|June 14, 2012
Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohortBryan T Alexander, Jonas Marschall, Robert J Tibbetts, et al.
Open Forum Infectious Diseases|November 22, 2021
Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort StudyDan Ilges, David J Ritchie, Tamara Krekel, et al.
Pharmacotherapy|January 27, 2007
Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundiiEli N Deal, Scott T Micek, David J Ritchie, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentScott T Micek, Ann E Lloyd, David J Ritchie, et al.
Clinical Therapeutics|January 4, 2011
Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort studyChristopher W Crank, Marc H Scheetz, Benjamin Brielmaier, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipientsNicholas S Britt, Samad Tirmizi, David J Ritchie, et al.
Annals of Laboratory Medicine|December 29, 2016
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative BacteriaMark D Gonzalez, Allison R McMullen, Meghan A Wallace, et al.
Chest|October 13, 2006
Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indicesMeghan N Jeffres, Warren Isakow, Joshua A Doherty, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa SepsisNicholas S Britt, David J Ritchie, Marin H Kollef, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Pharmacotherapy|April 10, 2002
Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: case report and literature reviewKristin E Mondy, Bruce Haughey, Philip L Custer, et al.
Clinical Therapeutics|June 14, 2012
Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohortBryan T Alexander, Jonas Marschall, Robert J Tibbetts, et al.
Open Forum Infectious Diseases|November 22, 2021
Assessment of Antibiotic De-escalation by Spectrum Score in Patients With Nosocomial Pneumonia: A Single-Center, Retrospective Cohort StudyDan Ilges, David J Ritchie, Tamara Krekel, et al.
Pharmacotherapy|January 27, 2007
Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundiiEli N Deal, Scott T Micek, David J Ritchie, et al.
Antimicrobial Agents and Chemotherapy|March 29, 2005
Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentScott T Micek, Ann E Lloyd, David J Ritchie, et al.
Clinical Therapeutics|January 4, 2011
Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort studyChristopher W Crank, Marc H Scheetz, Benjamin Brielmaier, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2017
Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipientsNicholas S Britt, Samad Tirmizi, David J Ritchie, et al.
Annals of Laboratory Medicine|December 29, 2016
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative BacteriaMark D Gonzalez, Allison R McMullen, Meghan A Wallace, et al.
Chest|October 13, 2006
Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indicesMeghan N Jeffres, Warren Isakow, Joshua A Doherty, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa SepsisNicholas S Britt, David J Ritchie, Marin H Kollef, et al.
Pageof 4